The identification of high quality, innovative small molecule leads remains a challenge in drug discovery. Innovative compound libraries are crucial in order to address the challenges associated with discovering new drugs. The chemical space to be sampled in drug discovery programs is vast and sparsely populated by existing compound collections. Therefore significant efforts and resources need to be invested in the generation and maintenance of competitive compound collections.
In this webinar, characteristics of a high-quality compound screening collection will be presented. AMRI’s approach to synthesizing compound screening collections is addressing this challenge by leveraging AMRI’s synthetic and medicinal chemistry expertise. This webinar will discuss AMRI’s cost-effective approach to the creation of high-value screening compounds.
Michael Trova, PhD, SVP, Drug Discovery Science, AMRI Global
Michael P. Trova, Ph.D., is senior vice president, Drug Discovery at AMRI, and responsible for leadership of the AMRI Global Discovery Services business. His current responsibilities include management of AMRI Discovery Services in Albany, N.Y.; Buffalo, N.Y.; Indianapolis; Windlesham, U.K., and Hyderabad, India. Dr. Trova is responsible for technical leadership and personnel development of his teams, as well as customer relationship development and discovery sales. He received his B.S. degree in chemistry at Rensselaer Polytechnic Institute, followed by a doctorate in organic chemistry from Ohio State University and postdoctoral research at the Massachusetts Institute of Technology.Message Presenter
Who Should Attend?
Senior level professionals from pharmaceutical and biotechnology companies, and research/academic institutions.
- Chemistry / Process Chemistry / Medicinal Chemistry
- Analytical Chemistry
- Analytical R&D
- Clinical Operations
- Chief Scientific Officers
- Research Scientists
What You Will Learn
- Required characteristics of a high-quality compound screening collection
- Synthetic and medicinal chemistry approaches to synthesizing compound screening collections
- A cost-effective approach to the creation of high-value screening compounds
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product.